Trials / Unknown
UnknownNCT00788177
Subretinal Macugen® for Neovascular Age-Related Macular Degeneration
Subretinal Macugen® for Neovascular Age-Related Macular Degeneration (SUMANA)
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Klinikum Ludwigshafen · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy of pegaptanib (Macugen®) for neovascular (exudative) age-related macular degeneration (AMD) when the first dose is administered to the submacular space instead of vitreous body in cases when previous state-of-the-art treatment for the AMD was deemed ineffective.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegaptanib (Macugen®) | Pegaptanib administered to the subretinal space (first dose) and to the vitreous cavity (following doses) |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2012-03-01
- Completion
- 2012-12-01
- First posted
- 2008-11-10
- Last updated
- 2011-09-27
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00788177. Inclusion in this directory is not an endorsement.